Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

Next Previous
Trial Profile

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms JUVE-X
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 24 Sep 2024 Planned End Date changed from 18 Dec 2030 to 1 Jul 2031.
  • 24 Sep 2024 Planned primary completion date changed from 18 Dec 2030 to 1 Jul 2031.
  • 18 Oct 2022 Planned End Date changed from 6 Dec 2027 to 18 Dec 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top